Approaches to the Individualized Management of MPNs: Best Practices and Guidance to Optimize Care

Outcomes are poor for patients with myelofibrosis who discontinue ruxolitinib due to loss of response or intolerance. In this commentary, I offer my thoughts on the best treatment options for these patients.

Srdan Verstovsek, MD, PhD Released: October 7, 2019

In this commentary, Raajit K. Rampal, MD, PhD, highlights key MPN studies that will be presented at the upcoming 2019 ASH annual meeting in Orlando.

Raajit K. Rampal, MD, PhD Released: December 2, 2019

Read expert answers to key questions from the audience at a recent symposium on optimal management of patients with myeloproliferative neoplasms.

Srdan Verstovsek, MD, PhD
Program Director Jean-Jacques Kiladjian, MD, PhD Raajit K. Rampal, MD, PhD Alessandro M. Vannucchi, MD Released: January 16, 2020